Company news: smartphones, Janssen, FDA

Share this article:
A study shows that smartphones are where the purchasing power is. According to research firm Deloitte, almost 50% of smartphone users say their phones helped them choose an item while bricks-and-mortar shopping, and  more than 33% of the users used a smartphone shopping app to help them decide. The fuss: Deloitte says this means smartphones have sealed $159 million in sales in just the first six months of this year, representing about 5.1% of in-store sales. Going forward four years, Deloitte says that number will jump to $689 billion in mobile-influenced sales, or 19% of in-store sales, while the industry estimates that the more linear direct mobile commerce will be $30 billion at that very same time.

Janssen-Cilag GmBH is adding a new heart failure treatment, known as COR-1, to its pipeline with one stroke: by acquiring privately-held Corlmmun for an undisclosed amount. The deal gives Janssen all rights to the drug, which is a small cyclic peptide.

The FDA Safety and Innovation Act is heading to the Oval Office for signature. Although the act is closely associated with user fees, the legislation's other implications include a provision that could speed up access to treatments for rare diseases. The legislation, which the Boston Herald notes was initially proposed as stand-alone legislation by Sen. Kay Hagen (D-NC), allows the FDA to expedite drug review under certain circumstances. There are about 7,000 rare diseases, but only 250 with FDA-approved treatments.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.